Tardive dyskinesia (TD) is an involuntary neurological movement disorder that is usually a side effect of certain dopamine receptor blocking drugs. It mainly affects the face but can also cause ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who ...

Kristin Weiland is a documentary film producer and writer with a background in crisis management and ethnographic research. She specializes in investigative and social impact documentary projects, and ...

Chorea and hemiballismus are both forms of involuntary movement disorders. Hemiballismus can cause sudden, violent, and flinging motions. Chorea can cause irregular, spontaneous, and nonrepetitive ...

SAN DIEGO, May 1, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its continued support of increasing awareness regarding the prevalence, impact and importance of ...

Adrian is the first paediatric patient with GNAO1 in Asia to undergo Deep Brain Stimulation surgery for this condition. SINGAPORE – Fewer than 500 people worldwide are known to have a rare genetic ...

Chorea-acanthocytosis is a rare genetic disorder of the nervous system. It causes involuntary jerks and twitches in the muscles, known as chorea, and star-shaped red blood cells, known as ...

The case description for a Case Records of the Massachusetts General Hospital appears below. What is the diagnosis? Cast your vote. The correct diagnosis, along with the full description of the case ...

Athetoid cerebral palsy is a type of cerebral palsy that causes uncontrollable muscle movements. It’s present in infancy or childhood and may be more severe than other types of cerebral palsy.

A 40-year-old man struggling with severe tremors and involuntary movements due to Parkinson’s Disease has found new hope after a life-changing procedure. His condition had worsened to the point where ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety ...